| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xue-Ping Huang, Yi-Juan Liu, Shao-Wei Lin, Yan-Feng Shao, Feng Qiu, Qing-Wu Qiu, Zhang-Kun Xu, Jin-Xian Chen, Liang-Huo Chen, Zhen-Qun Lin, Wen-Hua Dai, Ming-Qing Zhang, Qi Jiang, Zhong-Qin Xiao, Xian-Xing Cheng, Xiang-Fei Zhang, Wen-Bin You, Wei Chen, Long-Qin Li, Wei-Xing Lin, Yong-Fu Wang, Fu-Jin Lai, Long-Qun Chen, Zhong-Hua Huang, Wen-Qi Zheng, Jin-Qi Wei and Zhi-Hui Lin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Fujian Province |
No. 2020J011087 and No. 2022J011025 |
| Medical Innovation Project of Fujian Provincial Health Commission |
No. 2020CXA006 |
| Zhuhai Science and Technology Project |
No. 20181117E030040 |
|
| Corresponding Author |
Zhi-Hui Lin, MD, PhD, Chief Doctor, Department of Gastroenterology, Shengli Clinical Medical College of Fujian Medical University, No. 134 Dongjie, Gulou District, Fuzhou 350000, Fujian Province, China. fjslyylzh@fjmu.edu.cn |
| Key Words |
Helicobacter pylori; Vonoprazan; Amoxicillin; Dual therapy; Bismuth quadruple therapy |
| Core Tip |
Our study was a prospective, multicenter, randomized, two-stage study for Helicobacter pylori (H. pylori) eradication in Chinese population. We found that a daily dose of 20 mg of Vonoprazan was sufficient to eradicate H. pylori. We also found that compared to bismuth quadruple therapy, Vonoprazan-amoxicillin dual therapy with a duration of 10 days or 14 days, rather than 7 days, achieved higher eradication rates and that the safety profile of this dual therapy was more tolerable and manageable in Chinese patients. These results will guide further research and clinical practice for H. pylori eradication. |
| Publish Date |
2024-07-11 08:47 |
| Citation |
<p>Huang XP, Liu YJ, Lin SW, Shao YF, Qiu F, Qiu QW, Xu ZK, Chen JX, Chen LH, Lin ZQ, Dai WH, Zhang MQ, Jiang Q, Xiao ZQ, Cheng XX, Zhang XF, You WB, Chen W, Li LQ, Lin WX, Wang YF, Lai FJ, Chen LQ, Huang ZH, Zheng WQ, Wei JQ, Lin ZH. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study. <i>World J Gastroenterol</i> 2024; 30(27): 3304-3313</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i27/3304.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i27.3304 |
